A股異動丨貴州茅台股價跌至1470元,創2022年12月以來新低
貴州茅台(600519.SH)午後跌幅一度擴大至跌近2%,跌至1470.22元,創2022年12月以來新低。貴州茅台年內累跌超12%。截至昨日,北上資金連續4日淨賣出貴州茅台,共計37.12億元。另有數據顯示,貴州茅台是近期外資連續拋售期內成交量最大的股票,當前外資持股比例已經降至6.75%,為今年1月以來最低。消息面上,據酒價參考數據,茅台1935批發參考價今日跌破800元/瓶大關,報780元/瓶,已經出現價格“倒掛”的情況。茅台1935採用合同量計劃內外有別的進貨模式,其中計劃內價格為798元/瓶,計劃外價格為1088元/瓶,茅台1935是貴州茅台戰略性單品,去年銷售額超過100億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.